Grade Inflation: Why “Immunogen Grade” May Mean Less Than You Think

The Problem: Quality Labels Without Quality Standards

If you source proteins for antibody development, diagnostic manufacturing, or cell culture media, you routinely encounter labels like “immunogen grade,” “low endotoxin,” and “bioprocessing grade.” These descriptors appear on catalogs, Certificates of Analysis, and sales materials across the industry. They sound precise. They imply a level of quality control. And they influence purchasing decisions worth thousands of dollars per project.

But here’s the question that rarely gets asked: What do these terms actually mean?

Unlike pharmaceutical grades defined by USP or EP monographs, or ISO certification standards with published requirements, these descriptors have no regulatory definition, no consensus specification, and no third-party verification. Each supplier defines them independently—and most define them vaguely or not at all. As a result, two products bearing the same grade designation may differ substantially in purity profile, analytical characterization, and suitability for a given application. The label creates an illusion of comparability where none exists.

This guide will explain how these labels emerged, why they remain undefined, and what analytical approaches can give you genuine confidence in the proteins you source. We’ll focus primarily on “immunogen grade”—where inadequate definition carries the highest downstream risk—and then address the similar challenges with “low endotoxin” and “bioprocessing grade.”

“Immunogen Grade”: A Label in Search of a Definition

An immunogen is a molecule capable of eliciting an immune response when introduced into a host organism. When you use a protein as an immunogen—whether for polyclonal antibody production, monoclonal antibody development, or vaccine research—you need that protein to be the correct target, free of contaminants that could generate off-target immune responses, and of sufficient purity that the resulting antibodies or immune cells are specific to your intended target.^1,2

The term “immunogen grade” emerged organically in the reagent industry to signal that a protein preparation meets some higher bar of suitability for immunization. But unlike “USP grade” or “Grade A” in other industries, no standard-setting body has ever defined what “immunogen grade” requires. No pharmacopeia, no ISO committee, no industry consortium has published specifications for what qualifies.

What “Immunogen Grade” Typically Means Today

In practice, most suppliers who label a protein “immunogen grade” are relying on one or both of two analytical methods:

SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), often interpreted as showing a “single band” at the expected molecular weight

UV absorbance at 280 nm to estimate total protein concentration

If densitometry suggests a purity of “>90%” or “>95%,” the protein is labeled immunogen grade. While these methods are useful screening tools, they have important and well-documented limitations.

Key Limitations

Co-migration blindness. SDS-PAGE separates proteins by apparent molecular weight. Proteins of similar size can co-migrate, appearing as a single band even when multiple species are present. This is particularly relevant for complex proteins like immunoglobulins, where subclasses and fragments share similar molecular weights.^3,4

Limited sensitivity. Coomassie blue staining, the most common SDS-PAGE visualization method, has a detection limit of approximately 100 ng of protein per band. Impurities present at low levels—below roughly 1–2% of the total protein load—may go entirely undetected, even though they can profoundly affect an immunization outcome.^4,5

No identity confirmation. SDS-PAGE indicates approximate size, not molecular identity. A band at the expected molecular weight is assumed to be the target protein, but SDS-PAGE alone cannot distinguish the target from a co-migrating contaminant of similar mass. Only orthogonal methods—mass spectrometry, peptide mapping, or immunochemical detection—can confirm identity.^3,5,6

No compositional detail. For immunoglobulins and other heterogeneous proteins, the subclass distribution, fragments and isoforms can materially affect the immune response. SDS-PAGE provides none of this information.

The result is that a protein labeled “immunogen grade” based solely on gel data may contain undetected contaminants, may not be what the label claims, and may generate off-target immune responses that compromise months of work.

Analytical Methods for Protein Characterization: SDS-PAGE / UV Absorbance vs. LC-MS/MS

The following comparison illustrates why high-resolution LC-MS/MS provides a fundamentally different level of characterization than traditional gel-based methods:

• Protein identity confirmation: SDS-PAGE cannot confirm identity. LC-MS/MS provides definitive confirmation through peptide mapping.
• Detection of co-migrating species: SDS-PAGE cannot detect co-migrating proteins. LC-MS/MS resolves them by mass and sequence.
• Sensitivity to low-abundance impurities: SDS-PAGE has limited sensitivity (~1–2% detection threshold). LC-MS/MS achieves ~0.1% or better.
• Subclass or isoform distribution: SDS-PAGE provides no information. LC-MS/MS enables quantitative reporting.
• Contaminant identification: Not possible by SDS-PAGE. LC-MS/MS identifies contaminants through database matching.
• Lot-to-lot compositional comparison: SDS-PAGE provides only visual, subjective assessment. LC-MS/MS is quantitative and reproducible.
• Regulatory acceptance: SDS-PAGE is considered a screening method. LC-MS/MS is an accepted identity method under ICH Q6B.⁷

Why This Matters: The Downstream Consequences

The consequences of using a poorly characterized immunogen are practical and costly. In antibody development workflows, for example, immunization campaigns often span weeks to months and involve significant investments in animals, adjuvants, screening assays, and personnel time. If a contaminant constitutes even a small fraction of the immunogen, a substantial fraction of the resulting antibodies may target the wrong antigen.

For regulated IVD programs, the risk compounds. Discovery of an inadequately characterized immunogen late in development can trigger re-qualification or re-validation activities, adding six to eighteen months to timelines and creating substantial documentation burden under EU IVDR or FDA quality system requirements.

Setting a Real Standard: The Athens Pure™ Verified Approach

A meaningful immunogen-grade designation requires analytical methods commensurate with the quality claims being made. SDS-PAGE remains useful as a screening tool, but it is insufficient on its own to verify protein identity, purity, and composition.

Athens Pure™ Verified Immunogen Grade is a defined analytical standard, not a marketing tier. Every lot is characterized using high-resolution LC-MS/MS to provide objective, reproducible evidence of what the protein is and what else is present.

What LC-MS/MS Verification Provides

• Identity confirmation by peptide mapping. Each lot is enzymatically digested and analyzed on a high-resolution Orbitrap platform. Resulting peptide fragments are matched against the UniProt human proteome database, providing definitive confirmation that the protein is what the label says it is—not an assumption based on gel mobility.^6,7
• Compositional analysis. For multi-component proteins like immunoglobulins, we report the subclass distribution (IgG1, IgG2, IgG3, IgG4 Fc content) with quantitative relative abundance values derived from label-free spectral intensity analysis. This tells you not just that you have IgG, but what kind and in what proportions.
• Contaminant identification and quantification. Any detectable protein contaminants are identified by database search and reported with their relative abundance. Where SDS-PAGE provides a pass/fail visual impression, LC-MS/MS provides a complete compositional picture—including species present below SDS-PAGE’s detection threshold.
• Lot-specific reporting. Every Athens Pure™ Verified Certificate of Analysis (CoA) includes the actual LC-MS/MS data for that specific lot—not representative data, not typical values, and not specifications copied from a product master file. If the composition of Lot A differs from Lot B, you’ll know it.
• Transparent raw data access. Raw MS data are available upon request for customers who want to perform their own analysis or incorporate our data into their quality systems.

In short: Athens Pure™ Verified tells you what the protein is, what else is present, and in what proportions—for every lot.

See What an Athens Pure™ Verified CoA Looks Like. Request a sample Certificate of Analysis to see lot-specific LC-MS/MS data, subclass distribution reporting, and contaminant identification for any of our immunogen-grade products. Contact us at sales@athensbioscience.com.

“Low Endotoxin”: Another Label, Another Missing Standard

The challenge of undefined quality labels extends well beyond “immunogen grade.” The term “low endotoxin” (or “LEL”—Low Endotoxin Level) illustrates the same fundamental problem: widespread use without agreed definition.

What Endotoxins Are and Why They Matter

Endotoxins are lipopolysaccharide (LPS) molecules derived from the outer membrane of gram-negative bacteria. They are ubiquitous environmental contaminants, extremely heat-stable (surviving autoclaving), and potent activators of the innate immune system. In cell culture applications, endotoxin contamination can alter cell growth, viability, differentiation, and cytokine expression. In animal immunization studies, endotoxin acts as an uncontrolled adjuvant—potentially skewing immune responses in unpredictable ways.^8,9

For pharmaceutical parenterals, endotoxin limits are precisely defined: USP General Chapter <85> establishes a threshold pyrogenic dose of 5 EU/kg body weight per hour for most injectable products, with specific calculation methods for different routes of administration.^10,11 But for research-use proteins, cell culture supplements, and diagnostic reagents—where most life sciences purchasing occurs—no comparable standard exists.

The “Low Endotoxin” Landscape: A Survey of Inconsistency

Survey the catalogs of major protein suppliers and you’ll find “low endotoxin” specifications spanning three orders of magnitude. For example:

• Supplier A specifies “Low Endotoxin” at <10 EU/mg
• Supplier B specifies “Low Endotoxin” at <1 EU/mg
• Supplier C specifies “Ultra-Low Endotoxin” at <0.1 EU/mg
• Supplier D specifies “Endotoxin-Free” at <0.05 EU/mg

For reference, the USP <85> parenteral limit is 5 EU/kg/hr (dose-dependent)

All four suppliers above can legitimately claim their product is “low endotoxin.” But Supplier A’s product contains up to 200 times more endotoxin per milligram than Supplier D’s. For a cell culture application using 10 mg of protein in a bioreactor supplement, the difference could be 100 EU versus 0.5 EU—a range that can absolutely affect cell behavior.^8,9

Published research has demonstrated that even residual endotoxin contamination at levels within the “<1 EU” specification commonly guaranteed by suppliers can activate human dendritic cells, particularly the CD1c+ subpopulation. This means that proteins meeting a typical “low endotoxin” spec may still introduce enough endotoxin to compromise sensitive immunological experiments.⁹

What to Look For

Rather than relying on the “low endotoxin” label, informed buyers should evaluate three things:

the numerical endotoxin specification (in EU/mg or EU/µg),

the defined test method (e.g., kinetic LAL or recombinant Factor C), and

lot-specific reported results, not catalog specifications.

A supplier who reports “<1 EU/mg” as a specification and “0.08 EU/mg” as the actual measured value for a given lot is providing fundamentally more useful information than one who simply states “low endotoxin.”

Athens Bioscience reports quantitative endotoxin values on every lot-specific CoA using validated LAL testing, with specifications defined per product line. Our LEL (Low Endotoxin Level) products are manufactured with endotoxin minimization as an integral part of the purification process—not as an afterthought—and are tested against explicit numerical thresholds rather than undefined quality labels.

“Bioprocessing Grade”: Another Easy A?

A third undefined quality label gaining currency in the protein reagent industry is “bioprocessing grade” (sometimes “BPG” or “process grade”). This term typically signals that a protein—often transferrin, albumin, or a growth factor—is intended for use in cell culture manufacturing, bioprocessing, or therapeutic production environments.

The implied quality attributes are reasonable: high purity, low endotoxin, demonstrated biological activity, consistent lot-to-lot performance, and manufacturing under quality-controlled conditions. But once again, no regulatory body or standard-setting organization has defined what “bioprocessing grade” requires. The term means whatever each supplier decides it means.

Cell culture media manufacturers who use proteins labeled “bioprocessing grade” face a compounding risk. Their end customers—biopharma companies producing cell and gene therapies—are subject to cGMP requirements and regulatory inspections. If a media manufacturer cannot demonstrate that their raw materials meet defined specifications (not just marketing labels), their customers face potential regulatory findings.

Athens Bioscience defines its BioProcessing Grade products by explicit, documented criteria that include purity thresholds, quantitative endotoxin testing, functional activity assays, and comprehensive lot-specific CoA documentation. We define the standard rather than borrowing an undefined label.

A Practical Framework for Evaluating Quality Claims

Regardless of the label on a protein product, buyers can protect their programs by asking a consistent set of questions. Below are six key questions and what a strong answer looks like:

1. What analytical method underlies your purity claim? Look for orthogonal methods (MS, HPLC) beyond SDS-PAGE.
2. Is protein identity confirmed for each lot? Look for peptide mapping or MS-based identity testing.
3. Are contaminants identified or just excluded? Look for named contaminants with relative abundance.
4. Is your endotoxin spec a numerical threshold or a descriptor? Look for quantitative values (e.g., <0.5 EU/mg) with lot-specific results.
5. Does your CoA report lot-specific data or catalog specs? Look for actual measured values for each lot.
6. Can you provide raw analytical data upon request? Look for full transparency—a yes answer.

These questions shift the conversation from marketing terminology to measurable evidence.

Matching the Grade to the Application

Not every application requires LC-MS/MS-verified proteins. The key is matching the level of characterization to the risk profile of your application:

• Polyclonal antibody production: Minimum standard is SDS-PAGE >95%. Recommended standard is Athens Pure™ Verified (LC-MS/MS).
• Monoclonal antibody development: Minimum standard is SDS-PAGE >95%. Recommended standard is Athens Pure™ Verified (LC-MS/MS).
• IVD calibrator/control development: Minimum standard is application-dependent. Recommended standard is MS-verified identity plus functional assay.
• Cell culture media formulation: Minimum standard is low endotoxin. Recommended standard is BioProcessing Grade with quantitative specs.
• General research (ELISA, Western blot): Minimum standard is SDS-PAGE >90%. Standard research grade may suffice.
• Teaching or method development: Minimum standard is SDS-PAGE >85%. Standard research grade may suffice.

The more consequential and costly a downstream failure would be, the higher the standard of upstream characterization you should demand.

Conclusion: The Athens Standard Ends Grade Inflation

Quality descriptors are useful only when they are clearly defined and analytically supported. In the absence of agreed standards, labels such as “immunogen grade,” “low endotoxin,” and “bioprocessing grade” risk obscuring more than they reveal.

Athens Bioscience believes that when you put a quality label on a product you should be prepared to define exactly what it means and to provide the analytical data to back it up. Our Athens Pure™ Verified Immunogen Grade standard represents this philosophy in practice: mass spectrometry-verified identity, quantitative compositional reporting, transparent contaminant disclosure, and lot-specific data—all available to our customers as standard practice, not premium add-ons.

When a label has no agreed definition, demand the data. The analytical methods—not the marketing terms—tell you what you’re actually getting.

Ready to See the Difference? Athens Bioscience has specialized in native protein purification for over 40 years. With 170+ native human and animal proteins manufactured in our ISO 9001-certified USA facility, we can support your antibody development, diagnostic, and manufacturing applications with analytical quality you can verify. Talk to a protein expert, request a sample CoA, or explore our immunogen-grade products at www.athensbioscience.com.

References

1. Gruber, M.F. “Immunogenicity of Protein Pharmaceuticals.” J Pharm Sci, 2019; 108(5):1543–1547. doi:10.1016/j.xphs.2018.12.014

2. De Groot, A.S. et al. “T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation.” Front Immunol, 2020; 11:1301. doi:10.3389/fimmu.2020.01301

3. Raynal, B. et al. “Quality assessment and optimization of purified protein samples: why and how?” Microb Cell Fact, 2014; 13:180. doi:10.1186/s12934-014-0180-6

4. Mohan, S.B. “Determination of purity and yield.” Methods Mol Biol, 1992; 11:307–323. doi:10.1385/0-89603-213-2:307

5. Kilic, P. et al. “Residual protein analysis by SDS-PAGE in clinically manufactured BM-MSC products.” Electrophoresis, 2024; 45(13–14):1206–1219. doi:10.1002/elps.202300286

6. Mouchahoir, T. & Schiel, J.E. “Development of an LC-MS/MS peptide mapping protocol for the NISTmAb.” Anal Bioanal Chem, 2018; 410:2111–2126. doi:10.1007/s00216-018-0848-6

7. ICH Harmonised Tripartite Guideline Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. International Conference on Harmonisation, 1999.

8. Schwarz, H. et al. “Residual Endotoxin Contaminations in Recombinant Proteins Are Sufficient to Activate Human CD1c+ Dendritic Cells.” PLoS ONE, 2014; 9(12):e113840. doi:10.1371/journal.pone.0113840

9. Schwarz, H. et al. “Biological Activity of Masked Endotoxin.” Sci Rep, 2017; 7:44750. doi:10.1038/srep44750

10. United States Pharmacopeia, General Chapter <85> Bacterial Endotoxins Test. USP 43-NF 38, U.S. Pharmacopeial Convention, 2023.

11. FDA Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers. U.S. Food and Drug Administration, 2012.

12. FDA Guidance: Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products. U.S. Food and Drug Administration, 2020.

About Athens Bioscience

Since 1986, Athens Bioscience, Inc. (formerly Athens Research & Technology) has been a global leader in native protein purification. We manufacture 170+ native human and animal proteins in our ISO 9001:2015 certified, 11,000 square foot facility in Athens, Georgia. Our proteins are cited in over 1,500 peer-reviewed publications and trusted by industry leaders including Roche, Abbott, Siemens, and leading biopharma companies worldwide.

Contact:

U.S. Office: +1-706-546-0207 | sales@athensbioscience.com

European Office: +31-548-659-006 | europe@athensbioscience.eu

www.athensbioscience.com